Pharmagene plans IPO and signs six deals

Gene and protein expression company Pharmagene (Royston, U.K.) said it plans to raise 30-50 million ($45.1 million-$75.2 million) in an IPO on the London Stock Exchange. According to CEO Alistair Riddell, "we don't intend to return to the market for further funds." The company has three businesses: PhaseZero preclinical target identification and validation service; Pharmabase a database of human gene expression profiles to select and prioritize gene targets; and application of these technologies to revive previously failed compounds in new indications. ...